H5N1 bird flu is spreading across species. A new rapid response mRNA vaccine developed by Moderna could be a game‑changer for global pandemic preparedness. Meet Clare, one of the first volunteers in the CEPI-funded clinical trial, as she gets her first dose.

CEPI and Pasteur Network have signed a Memorandum of Understanding to expand collaboration on epidemic and pandemic preparedness, vaccine research, manufacturing and innovation. More ⬇️

Our #100DaysMission aims to accelerate vaccine development timelines to 100 days. Had this been achieved for COVID-19, around eight million lives might have been saved. Discover the 100 Days Mission: https://cepi.net/100-days-mission

The CEPI 3.0 Investment Case calls for US$2.5 billion in new funding to unlock the plan’s transformational epidemic and pandemic-busting potential and secure a safer, better prepared future for all. Read the details ⬇️ #SecureTheFuture https://bit.ly/4cqqNjc

For an interview with France's L'Express, CEPI’s Deputy CEO, Aurélia Nguyen, reflects on the growing role of artificial intelligence in epidemic and pandemic preparedness, including the potential biosecurity risks. More: https://bit.ly/4cldTmv

Could the key to stopping future pandemics be… right under our noses? 👃🦠 Imperial is leading @musiccproject.bsky.social, a global project exploring #vaccines that could block infection at the point of entry. Read more in this @cepi.net blog 👇 cepi.net/could-our-no...

CEPI and Pan American Health Organization are expanding their exisiting partnership to help strengthen regulatory systems and pharmacovigilance across Latin America and the Caribbean, supporting more agile approvals and improved vaccine safety monitoring. More: cepi.net/cepi-and-pah...

"The 100 Days Mission reflects our shared commitment to deliver faster, safer and more effective preparedness and response for all countries." A powerful message of support for CEPI 3.0 and the 100 Days Mission from Indonesia's Minister of Health, Budi Sadikin ⬇️

CEPI CEO Richard Hatchett sets out why pandemic preparedness remains a global priority. From the growing threat of emerging diseases, including the potential misuse of AI, to declining investment in public health, the risks are evolving. At the same time, the tools to respond are improving. More ⬇️

Our March newsletter has just landed 🗞️ This month zooms in on how regulatory preparedness will be a crucial enabler of the 100 Days Mission. It also features all the regular updates, including CEPI 3.0 campaign progress, our latest R&D partnerships and plenty more.

Late last year, CEPI, @path.org and Africa CDC convened 80+ experts from 20 countries in Nairobi to move RPECA from concept to a concrete roadmap that establishes a regionally owned ecosystem for rapid clinical trials and real-world evidence generation. Discover the key takeaways: bit.ly/4rVQopT

📣Positive topline results from a CEPI-supported study of Bavarian Nordic's Mpox vaccine in 2-to-11-year-olds have been submitted to the European Medicines Agency, paving the way for the jab to be approved for use in younger age groups: www.bavarian-nordic.com/investor/new...

A new Springer Nature perspective featuring @Pfizer leaders explores how to make the 100 Days Mission a reality. Read the full article: link.springer.com/article/10.1...

Strengthening capabilities needed to advance a Lassa fever vaccine are also the same capabilities needed to ensure any vaccine can be developed, whether that’s for a known disease like Lassa fever or a future Disease X. This approach sits at the heart of CEPI 3.0 and the 100 Days Mission. More ⬇

The 100 Days Mission is the benchmark for pandemic preparedness, but achieving it requires more than scientific breakthroughs. It requires a shift from individual vaccines to building the broad capabilities needed for rapid response. More in our new blog ⬇️

The University of Oxford and Serum Institute of India have signed an IP licensing agreement to advance development and manufacturing of the CEPI-funded ChAdOx1 NipahB vaccine candidate - an important step toward strengthening global preparedness against Nipah virus.

CEPI strengthens global biosecurity with eight new partnerships ⬇️ The partnerships will help advance our biosecurity work. Selected through a competitive Request for Proposals, these organisations are global leaders in training, policy, laboratory infrastructure, and biorisk management.

"The 100 Days Mission is a game-changer" - H.E Dr Jean Kaseya, Director General, Africa CDC. In this supportive statement from Africa CDC, Dr Kaseya explains how CEPI's 100 Days Mission is helping the continent to #SecureTheFuture against the threat of epidemics and pandemics.

"In less than 10 years, CEPI has helped to redefine how the world develops vaccines for emerging infectious diseases, shifting from reactive crisis response to collaborative preparedness." - Dr Tedros Adhanom Ghebreyesus. A powerful endorsement of CEPI 3.0 from our @who.int partners.

Our February newsletter is live! It spotlights the launch of CEPI 3.0 Investment Case and Strategy. Inside, you’ll find a deep dive into our next strategic phase, messages of support, a dedicated reading corner and more.

A great video from our partners on the impact that CEPI's funding is having on clinical trial preparedness in the West Africa region ⬇️

Epidemics & pandemics are a defining #HealthSecurity challenge of our time. @cepi.net#HealthSecurityis working to transform the way we tackle today’s viral threats and get ahead of tomorrow’s. CEPI's 3.0 strategy aims to secure a safer, better prepared future for all: https://bit.ly/4cFE2y9 #SecureTheFuture

The Biospecimen Sourcing Initiative aims to facilitate the timely and ethical collection of biological samples during an outbreak: https://bit.ly/4qILZWZ Biospecimens from survivors are necessary for the rapid development of new vaccines, treatments & diagnostics. #100DaysMission @cepi.net

A new All Africa feature highlights both the progress made against Ebola — and the work still ahead — drawing on insights from CEPI CEO Richard Hatchett.

In mid-2025, CEPI welcomed its second cohort of Global South Fellows. Now, halfway through the year-long fellowship, we caught up with Dr Umar Ahmad—one of the Fellows embedded in CEPI’s Laboratory Research and Innovations department—to discuss his experience. Read the Q&A blog to learn more ⬇️

Promising Lassa vaccine candidates are in clinical development, one of which could be licensed in the next decade. ✏️We must start planning now to translate this progress into protection, write CEPI's Oyeronke Oyebanji and WAHO's Virgil Lokossou in @projectsyndicate.bsky.social:

As we build momentum for CEPI 3.0 (2027–2031), we’re sharing messages from across our Coalition, showing why investment is key to securing the future from epidemic and pandemic threats. Below, Gavi CEO Dr Sania Nishtar shares her support and how our organisations collaborate to protect everyone.

“We invest in CEPI because it makes Norway safer, and it makes the world safer” — Jonas Gahr Støre, Prime Minister of Norway. In a new message marking the launch of our CEPI 3.0 Investment Case, Norway’s Prime Minister underscores why sustained investment in CEPI matters, nationally and globally.

Today marks the launch of the CEPI 3.0 Investment Case and Strategy. CEPI 3.0 – our 2027-2031 strategy - is the next step in CEPI’s mission to transform the way the world tackles epidemic and pandemic threats. Discover more in the press release ⬇️

At #MSC2026, CEPI is partnering with @ForeignPolicy to host an official side event on the #100DaysMission—bringing science, policy & security together to accelerate responses to future biological threats. 📍 Munich | 🗓️ 14 Feb | ⏰ 09:30 CET 🔗 Request to attend in person or online:

This week CEPI is hosting a fictional pandemic simulation exercise in Seoul with Korea's Ministry of Food Drug & Safety, the Korea Disease Control and Prevention Agency and IVI. The expert meeting will explore opportunities to strengthen Korea's readiness to rapidly respond to a future viral threat⤵️

📣💡 With the prospect of protection against Lassa fever closer than ever before, CEPI and the West African Health Organization (WAHO) have launched the first end-to-end access roadmap for Lassa fever vaccines. Read more:

Samsung Biologics becomes the latest organisation to join CEPI's Vaccine Manufacturing Facility Network (VMFN) -- a globally distributed manufacturing ecosystem designed to enable rapid and equitable access to vaccines in future pandemics. More: cepi.net/cepi-and-sam...

Check out CEPI's first newsletter of 2026 🗞️ This month spotlights new partnerships to expand access to Ebola vaccines. It also includes our latest R&D and manufacturing news and all the other regular features. www.linkedin.com/pulse/closin...

The 100 Days Mission 5th Implementation Report is now available. The report, produced by @ippsecretariat.org, reflects a pivotal year for pandemic preparedness, reviewing recent progress and setting out priorities for 2026. 📘 bit.ly/100dm-5th-re...

AI is becoming a critical tool in how the world responds to infectious disease threats. In a new WEF blog, CEPI CEO Richard Hatchett and Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen explore how AI-enabled platforms can help close the gap between pathogen detection & vaccine development.

Are you attending the 2026 @MunSecConf? If so, be sure to add CEPI and Foreign Policy's official side event to your list: The 100 Days Mission: Defending Against Pandemic and Biological Risks in a Fragmented World ⬇️ foreignpolicy.com/events/fp-ms...

A new @el_pais article explores how Africa is strengthening its end-to-end vaccine development to build vaccine sovereignty and respond faster to future outbreaks, featuring insights from CEPI’s Amadou Sall. Read more: elpais.com/planeta-futu...

“Standardized clinical assays, diagnostic assays and, ultimately, a vaccine are needed to prepare for future Nipah virus outbreaks.” A CEPI-led publication in @Nature Health explores what the world needs to respond effectively to #Nipah outbreaks. www.nature.com/articles/s44...

🎙️ How do you stop a pandemic before it starts? CEPI’s Valentina Bernasconi and Charles River’s Marie-Eve Poupart break it down: vaccines, lab tools & preparpring for a Disease X. Listen to the full podcast: www.criver.com/eureka/plann...

Our new short communication in Vaccine outlines CEPI’s Coronavirus Vaccine Library: a preparedness effort to build and share antigen designs, assays and data across priority coronaviruses. Read in full: sciencedirect.com/science/arti...

Amid a Rift Valley fever outbreak in West Africa, the Nuffield Department of Medicine @ox.ac.uk and Serum Institute of India have entered into a $3.5m agreement supported by CEPI to create the world’s largest reserve of Oxford’s investigational Rift Valley fever vaccine💉

Can scientists design an all-in-one vaccine to protect against multiple deadly viruses, including Ebola, Sudan and Marburg? @ox.ac.uk and partners, including the University of Leipzig and Moderna, are leading a new project with $26.7m from CEPI and @horizoneu.bsky.social. cepi.net/ambitious-re...

AI is revolutionising how science can protect the world and its people against the threat of infectious disease outbreaks. Learn how CEPI is harnessing the power of AI to transform vaccine development for future epidemics or pandemics. https://cepi.net/artificial-intelligence

CEPI’s Biosecurity Strategy—supported by funding from Global Affairs Canada—aims to bolster global health security, underscoring its commitment to tackling emerging epidemic and pandemic threats, whether they arise naturally, accidentally or through deliberate misuse. https://cepi.net/biosecurity

ICYMI: Check out CEPI CEO Dr Richard Hatchett's 2025 end of year reflections. https://bit.ly/49iV573

The viruses that put humanity at greatest risk to date come from 25 or so virus families. It is these families that are most likely to produce the next deadly viral threat. https://bit.ly/3EUmaAN

To date, CEPI has made investments in over 75 vaccine candidates or platform technologies. This includes advancing research against: 🔵 COVID-19 🔵 MERS 🔵 Nipah 🔵 Lassa fever 🔵 Chikungunya 🔵 Rift Valley fever 🔵 Disease X 🔵 Ebola Find out more 👇https://cepi.net/priority-pathogens

What if it took 100 days to make a safe and effective vaccine against any virus? We could stay one step ahead of infectious diseases and outbreaks could be stopped before they ever spiralled into pandemics #100DaysMission https://cepi.net/cepi-20-and-100-days-mission

The Biospecimen Sourcing Initiative is a new global resource that aims to facilitate the timely, coordinated and ethical sourcing of biospecimens in an outbreak. Specimens provide scientists with insights into the virus and how the body fends off an infection ⤵️ @path.org cepi.net/disease-outb...